Clinical trialNCT07221227RecruitingPhase 3Interventional

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

SponsorGlaxoSmithKlineEnrollment1,200Non-alcoholic Fatty Liver Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

GSK Clinical Trials
GlaxoSmithKline
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

91 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Gsk Investigational Site
Broadmeadow, New South Wales, Australia
Lay Theng Gan
Recruiting
Gsk Investigational Site
Heidelberg, Victoria, Australia
Marie Sinclair
Recruiting

Canada

Gsk Investigational Site
Québec, Quebec, Canada
Pascale Chouinard
Recruiting

Hong Kong

Gsk Investigational Site
Pokfulam, Hong Kong
Loey Lung Yi Mak
Recruiting

Japan

Gsk Investigational Site
Gifu, Japan
Hidenori Toyoda
Recruiting
Gsk Investigational Site
Kanagawa, Japan
Kento Imajo
Recruiting
Gsk Investigational Site
Kyoto, Japan
Yuya Seko
Recruiting
Gsk Investigational Site
Musashino, Japan
Nobuharu Tamaki
Recruiting
Gsk Investigational Site
Yokohama, Japan
Michihiro Iwaki
Recruiting

New Zealand

Gsk Investigational Site
Wellington, New Zealand
Stephen Inns
Recruiting

Puerto Rico

Gsk Investigational Site
San Juan, Puerto Rico
Grisell Ortiz-Lasanta
Recruiting

Saudi Arabia

Gsk Investigational Site
Riyadh, Saudi Arabia
Khalid Alswat
Recruiting

Taiwan

Gsk Investigational Site
Chiayi City, Taiwan
Chen Chi-Yi
Recruiting
Gsk Investigational Site
Kaohsiung City, Taiwan
Ming-Lung Yu
Recruiting
Gsk Investigational Site
Kaohsiung City, Taiwan
Tsung-Hui Hu
Recruiting

United States

Gsk Investigational Site
Chandler, Arizona, United States
Anita Kohli
Recruiting
Gsk Investigational Site
Tucson, Arizona, United States
Hani Rizk
Recruiting
Gsk Investigational Site
Little Rock, Arkansas, United States
John Baber
Recruiting
Gsk Investigational Site
Arcadia, California, United States
Elias Tarakji
Recruiting
Gsk Investigational Site
Covina, California, United States
Masoud Azizad
Recruiting
Gsk Investigational Site
Folsom, California, United States
Nazir Rahim
Recruiting
Gsk Investigational Site
Los Angeles, California, United States
Joseph Lamb
Recruiting
Gsk Investigational Site
Montclair, California, United States
Rizwana Mohseni
Recruiting
Gsk Investigational Site
Riverdale, California, United States
Deon Miller
Recruiting
Gsk Investigational Site
San Diego, California, United States
Julie Doan Trang Vu
Recruiting
Gsk Investigational Site
Santa Maria, California, United States
Keval Shah
Recruiting
Gsk Investigational Site
Van Nuys, California, United States
Robert Jenders
Recruiting
Gsk Investigational Site
Colorado Springs, Colorado, United States
Bhaktasharan Patel
Recruiting
Gsk Investigational Site
Boynton Beach, Florida, United States
Aaron Cohen
Recruiting
Gsk Investigational Site
Cape Coral, Florida, United States
Paige Kreegel
Recruiting
Gsk Investigational Site
Clermont, Florida, United States
Edriss Estime
Recruiting
Gsk Investigational Site
Fort Myers, Florida, United States
Charles Smith
Recruiting
Gsk Investigational Site
Hialeah, Florida, United States
Isaac Bassan
Recruiting
Gsk Investigational Site
Hialeah, Florida, United States
Jorge Diaz
Recruiting
Gsk Investigational Site
Homestead, Florida, United States
Gilberto Seco
Recruiting
Gsk Investigational Site
Inverness, Florida, United States
Paul Hellstern Jr.
Recruiting
Gsk Investigational Site
Jacksonville, Florida, United States
Jeffry Jacqmein
Recruiting
Gsk Investigational Site
Kissimmee, Florida, United States
Luis Alvarado Lopez
Recruiting
Gsk Investigational Site
Lakeland, Florida, United States
James Andersen
Recruiting
Gsk Investigational Site
Maitland, Florida, United States
Eva Maria Heurich
Recruiting

51 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Efimosfermin alfaPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Oct 2025
Primary completion: 29 Mar 2028
Completion: 12 Dec 2031
Last update posted: 27 Jul 2026
Registered enrollment: 1,200
Registry id: NCT07221227

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-523675-39

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.